Press release

Siemens Healthineers launches the company’s New Ambition phase with changes to the Managing Board

Published on November 16, 2021
<ul> <li><b>Elisabeth Staudinger appointed to Managing Board</b></li><b> <li>Christoph Zindel to leave Managing Board at own request in spring 2022</li> <li>New allocation of responsibilities</li></b></ul> <p>To coincide with the start of the company’s New Ambition phase, Elisabeth Staudinger (51), Head of Siemens Healthineers in the Asia Pacific region since April 2018, has been appointed as a member of the Managing Board, effective December 1, 2021. At the same time the Supervisory Board of Siemens Healthineers AG has accepted the resignation of Dr. Christoph Zindel (60) as of March 31, 2022, due to personal circumstances.</p> <p><i>“Under the leadership of Elisabeth Staudinger, the Siemens Healthineers business in Asia, and particularly in China, has made excellent progress. Her extraordinarily wide and substantial spectrum of experience, ranging from strategic procurement at Siemens AG and manufacturing activities to extensive regional and global business responsibility at Siemens Healthineers, makes Elisabeth Staudinger an excellent manager and outstanding leadership personality. With her appointment to the Managing Board, we are also strengthening our international profile,” said Prof. Dr. Ralf P. Thomas, Chairman of the Supervisory Board of Siemens Healthineers AG. “On behalf of the Supervisory Board, I would like to thank Dr. Christoph Zindel for his deep dedication and everything he has achieved for the company over the years. Under his management, the Imaging and Advanced Therapies segments developed excellently. He also played a major role in advancing the Siemens Healthineers sustainability program. The Supervisory Board regards his early notification of his personal plans as indicative of his commitment to Siemens Healthineers, which enables us to make a smooth transition regarding the reassignment of responsibilities.“</i></p> <p>In conjunction with these personnel-related changes to the Managing Board, the assignments of Segments, Businesses and Regions have also been reorganized. As of December 1, 2021, responsibilities are allocated as follows for the Managing Board of Siemens Healthineers AG:</p> <ul> <li>Bernd Montag is responsible at Board level for the Imaging, Diagnostics, Varian and Advanced Therapies segments.</li> <li>Jochen Schmitz is responsible at Board level for Finance and for the Europe/Middle East/Africa (EMEA) region.</li> <li>Darleen Caron is responsible at Board level for Human Resources and for the Americas (AM) region.</li> <li>Elisabeth Staudinger is responsible at Board level for the Asia Pacific (AP) region, global Customer Service as well as Technology Excellence (TE), the global unit for company-wide technology management, with joint components and software development.</li> <li>Christoph Zindel is responsible for the Ultrasound Business Area until the end of March 2022.</li> </ul> <p>Between 1998 and 2004, Elisabeth Staudinger had multiple roles in various operative capacities at Siemens AG in Germany, Singapore and China. She then held positions between 2005 and 2009 which included management functions in the areas of procurement and controlling, as well as in manufacturing. From 2009 to 2013 she was Head of global business for refurbished systems. Since 2013 she has been responsible for the overall business of Siemens Healthineers in Asia in a variety of management roles. She studied economics, Sinology and history in Vienna, Beijing, and Nanjing.</p>

Siemens Healthineers 2022

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care. In fiscal 2021, which ended on September 30, 2021, Siemens Healthineers, which has approximately 66,000 employees worldwide, generated revenue of €18.0 billion and adjusted EBIT of €3.1 billion. Further information is available at